Julian J.K. Lohmeyer

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

Constanze Schneider, Thomas Oellerich, Hanna‐Mari Baldauf et al. · Nature Medicine · 2016 · 185 citations

Medicine, Oncology, Pharmacology +14

An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory

Ole Audun Werner Haabeth, Julian J.K. Lohmeyer, Adrienne Sallets et al. · ACS Central Science · 2021 · 68 citations · Full text

Pharmacy, Biotechnology, Immunology +17

CD20-Targeted Therapy Ablates <i>De Novo</i> Antibody Response to Vaccination but Spares Preestablished Immunity

Tanaya Shree, Vishnu Shankar, Julian J.K. Lohmeyer et al. · Blood Cancer Discovery · 2022 · 48 citations · Full text

Medicine, Immunology, Oncology +17

Intratumoral immunotherapy relies on B and T cell collaboration

Idit Sagiv-Barfi, Debra K. Czerwinski, Tanaya Shree et al. · Science Immunology · 2022 · 41 citations · Full text

Life Sciences, Immunology, Oncology +17

An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory

Ole Audun Werner Haabeth, Julian J.K. Lohmeyer, Adrienne Sallets et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2021 · 11 citations · Full text

Pharmacy, Biotechnology, Immunology +17